Craig Mayer, Nick WIlliams, Vojtech Huser
Lister Hill National Center for Biomedical Communications, National Library of Medicine, NIH, Bethesda, MD

See the full regCTG repository at https://github.com/lhncbc/CRI/tree/master/regCTG

To return to the list of conditions and view other reports go to https://lhncbc.github.io/CRI/regCTG/regCTG-condition_report_links.html


Study Counts

Type Study_count
Total_Studies 367
interventional 335
Observational 31
Registry 1

Studies over Time by Start Date

```

Interventional Trials

Intervention Type

intervention_type Study_Count
Drug 144
Drug|Other 32
Biological 26
Biological|Drug|Other 23
Biological|Drug 22
Biological|Other 11
Biological|Drug|Procedure|Radiation 7
Drug|Radiation 7
Drug|Other|Procedure|Radiation 6
Biological|Drug|Other|Procedure|Radiation 5
Biological|Other|Procedure 4
Drug|Other|Procedure 4
Drug|Procedure 4
Drug|Procedure|Radiation 4
Biological|Drug|Other|Procedure 3
Biological|Drug|Radiation 3
Drug|Genetic|Other 3
Biological|Drug|Procedure 2
Biological|Other|Radiation 2
Biological|Radiation 2
Drug|placebo 2
Procedure 2
Radiation 2
Biological|Device|Drug|Procedure|Radiation 1
Biological|Drug|Genetic 1
Biological|Drug|Genetic|Other 1
Biological|Drug|Genetic|Other|Procedure 1
Biological|Drug|Other|Radiation 1
Biological|Genetic|Other 1
Biological|Genetic|Other|Procedure 1
Biological|Procedure|Radiation 1
Combination Product|Drug|placebo 1
Dietary Supplement|Other 1
Drug|Genetic|Other|Procedure|Radiation 1
Drug|Genetic|Procedure|Radiation 1
Drug|placebo|Procedure 1
Other 1
Other|Procedure 1

Count of Studies by Intervention (normalized and mapped)

Interventions over Time

Yearly studies for each intervention by start date

Studies by Country

Country Study_Count
United States 196
China 13
Italy 10
France 7
Germany 6
NA 6
United States|Canada 6
Canada 4
United States|Italy 4
United States|Germany|Italy 3
Australia 2
Belgium|France 2
Japan 2
Norway 2
Russian Federation 2
Spain 2
United States|Australia|Italy 2
United States|Germany 2
Argentina|Australia|Austria|Brazil|Bulgaria|Colombia|France|Germany|Greece|Hungary|India|Ireland|Israel|Italy|Japan|Malaysia|Netherlands|Peru|Poland|Portugal|Romania|Russian Federation|South Africa|Spain|Ukraine|United Kingdom 1
Argentina|Australia|Belgium|Brazil|Colombia|Denmark|France|Netherlands|New Zealand|Peru|Spain|Thailand 1
Argentina|Australia|Brazil|Canada|Czech Republic|Denmark|Ecuador|Finland|France|Israel|Italy|Korea, Republic of|Mexico|Norway|Peru|Poland|Russian Federation|Slovakia|Spain|Sweden|Switzerland|United Kingdom 1
Australia|Austria|Belgium|Croatia|Czechia|France|Germany|Greece|Hungary|New Zealand|Poland|Russian Federation|Spain 1
Australia|Belgium|Canada|France|Germany|Italy|Portugal|Spain 1
Australia|Canada|France|Italy|Sweden|Switzerland 1
Australia|Canada|New Zealand 1
Australia|France|Germany|Italy|Spain|United Kingdom 1
Austria|Denmark|Finland|Norway|Sweden|Switzerland 1
Austria|Switzerland 1
Belgium|Canada|Denmark|France|Germany|Italy|Netherlands|Norway|Portugal|Spain|Sweden|Switzerland|United Kingdom 1
Colombia|India|Russian Federation|South Africa|Ukraine 1
Czechia|Norway|Poland|United Kingdom 1
Denmark 1
France|Italy|Poland|Taiwan|Ukraine|Germany|United States|Australia|Canada|United Kingdom 1
France|United Kingdom 1
Hungary 1
Hungary|Argentina|Australia|Austria|Brazil|Canada|Chile|Colombia|Croatia|Denmark|Dominican Republic|Egypt|El Salvador|Germany|Guatemala|Hong Kong|Indonesia|Italy|Korea, Republic of|Malaysia|Netherlands|New Zealand|Panama|Peru|Philippines|Portugal|Romania|Sweden|Taiwan|Thailand|Turkey|Vietnam 1
Japan|Korea, Republic of 1
Korea, Republic of 1
New Zealand 1
Norway|Sweden|Switzerland 1
Poland 1
Spain|United States|France 1
Switzerland 1
United Kingdom 1
United States|Argentina|Australia|Belgium|Brazil|Canada|China|Colombia|Czechia|France|Germany|Greece|Hungary|Ireland|Israel|Italy|Korea, Republic of|Mexico|Netherlands|Poland|Portugal|Russian Federation|Spain|Sweden|Taiwan|Turkey|Ukraine|United Kingdom 1
United States|Australia 1
United States|Australia|Austria|Belgium|Canada|Czechia|France|Greece|Hungary|Israel|Italy|Netherlands|New Zealand|Poland|Portugal|Russian Federation|Spain|Taiwan|Turkey|United Kingdom 1
United States|Australia|Austria|Belgium|France|Germany|Italy|Japan|Netherlands|Norway|Spain|United Kingdom 1
United States|Australia|Austria|Belgium|France|Germany|Italy|Korea, Republic of|New Zealand|Poland|Spain|Switzerland|Taiwan|United Kingdom 1
United States|Australia|Belarus|Bulgaria|Canada|China|Czechia|France|Germany|Italy|Korea, Republic of|New Zealand|Poland|Russian Federation|Spain|Taiwan|United Kingdom 1
United States|Australia|Belgium|Canada|France|Germany|Italy|Norway|Singapore|Spain|Sweden|United Kingdom 1
United States|Australia|Belgium|Canada|France|Germany|Italy|United Kingdom 1
United States|Australia|Belgium|Canada|France|Italy|Spain 1
United States|Australia|Belgium|France|Germany|Poland|Russian Federation|Spain|United Kingdom 1
United States|Australia|Canada|Czechia|Denmark|Germany|Hungary|Israel|Italy|Poland|Spain|Sweden|United Kingdom 1
United States|Australia|Canada|Czechia|France|Israel|Italy|Poland|Romania|Spain|United Kingdom 1
United States|Australia|Chile|Czechia|France|Germany|Hungary|Italy|Korea, Republic of|Mexico|South Africa|Spain|Turkey|United Kingdom 1
United States|Australia|France|Italy|Japan 1
United States|Austria|Belarus|Belgium|Brazil|Croatia|France|Georgia|Germany|Greece|India|Italy|Japan|Korea, Republic of|Lebanon|Mexico|Peru|Philippines|Poland|Portugal|Puerto Rico|Romania|Russian Federation|South Africa|Spain|Switzerland|Thailand|Turkey|Ukraine|United Kingdom 1
United States|Austria|Belgium|Bulgaria|Czechia|Denmark|France|Germany|Hungary|Italy|Poland|Romania|Russian Federation|Slovakia|Spain|Ukraine|United Kingdom 1
United States|Austria|France|Germany 1
United States|Belgium|Canada|Germany|Korea, Republic of 1
United States|Belgium|Canada|United Kingdom 1
United States|Belgium|France|Germany|Italy|Korea, Republic of|Spain|Turkey 1
United States|Brazil|Germany|Japan|Netherlands|Spain|United Kingdom 1
United States|Canada|France|Italy 1
United States|Canada|Germany 1
United States|Canada|Singapore 1
United States|Czechia|Denmark|Hungary|Italy|Spain 1
United States|Denmark|Germany 1
United States|France 1
United States|France|Germany|Italy|Poland|United Kingdom 1
United States|France|Germany|Italy|United Kingdom 1
United States|France|United Kingdom 1
United States|Germany|Poland 1
United States|Italy|Russian Federation|Spain 1
United States|Italy|United Kingdom 1
United States|Japan 1
United States|Puerto Rico 1
United States|Spain 1
United States|Spain|United Kingdom 1
United States|United Kingdom 1

Sites per Study

Site_count Study_Count
1 151
2 20
3 14
4 9
5 12
6 10
7 9
8 1
9 2
10 2
11 9
12 8
13 3
14 3
15 3
16 4
17 3
19 2
20 3
21 6
22 2
23 4
24 3
25 2
26 1
28 2
29 1
30 2
33 1
34 1
35 3
37 1
40 1
41 2
42 3
43 2
44 2
45 1
47 1
48 1
50 1
52 2
54 1
62 2
71 1
79 1
80 1
85 1
87 1
91 1
95 1
96 1
104 1
114 1
129 1
131 1
152 1
164 1
176 1
227 1
246 1
396 1
423 1

Phase

Phase Study_Count
Phase 2 131
Phase 1 106
Phase 1/Phase 2 43
Phase 3 38
N/A 12
Early Phase 1 4
Phase 4 1

Number of Arms

Number_of_Arms Count_of_Studies
1 214
2 68
3 18
4 9
5 3
6 4
7 1
10 1
NA 17

Enrollment Metrics by Phase

Measure Early.Phase.1 N.A Phase.1 Phase.1.Phase.2 Phase.2 Phase.3 Phase.4
Min. 15.00 5.00000 1.00000 7.00000 7.00000 14.0000 112
1st Qu. 15.75 25.25000 20.00000 31.00000 41.00000 167.5000 112
Median 23.00 58.50000 37.00000 40.00000 60.00000 275.0000 112
Mean 23.50 73.66667 51.73333 66.69767 74.42748 378.7895 112
3rd Qu. 30.75 102.25000 60.00000 95.50000 97.00000 448.2500 112
Max. 33.00 200.00000 281.00000 420.00000 279.00000 1337.0000 112

Trial Group Type

group_type Group_Count
Experimental 433
Active Comparator 41
NA 17
Other 8
No Intervention 7
Placebo Comparator 6
Sham Comparator 1

Intervention Model

intervention_model Study_Count
Single Group Assignment 234
Parallel Assignment 83
Sequential Assignment 13
NA 3
Factorial Assignment 2

Primary Purpose

primary_purpose Study_Count
Treatment 321
Supportive Care 8
Basic Science 2
Other 2
Prevention 2

Observational Studies

Studies by Country

Country Study_Count
NA 8
France 3
United States 3
Germany 2
Italy 2
Korea, Republic of 2
Serbia 2
Austria|Belgium|France|Germany|Greece|Ireland|Italy|Portugal|Spain|Sweden|United Kingdom 1
Belgium 1
Brazil 1
Canada 1
China|Hong Kong|Taiwan 1
France|Italy 1
Italy|Switzerland 1
Macedonia, The Former Yugoslav Republic of 1
United States|Australia|Canada|Puerto Rico 1

Sites per Study

Site_count Study_Count
1 21
4 3
6 2
22 1
27 1
48 1
83 1
130 1

Enrollment Metrics

Measure Observational
Min 12.0000
1st Qu 97.0000
Median 180.0000
Mean 822.9677
3rd Qu 317.5000
Max 13433.0000

Observation Model

observational_model Study_Count
Cohort 18
Other 4
NA 4
Case-Only 3
Case-Control 1
Case Control 1

Time Perspective

time_perspective Study_Count
Retrospective 16
Prospective 12
Other 2
NA 1

Registries

Studies by Country

Country Study_Count
United States 1

Sites per Study

Site_count Study_Count
11 1

Enrollment Metrics

Measure Registries
Min 200
1st Qu 200
Median 200
Mean 200
3rd Qu 200
Max 200

Registry Model

observational_model Study_Count
Cohort 1

Time Perspective

time_perspective Study_Count
Prospective 1

Follow-up

target_duration Study_Count
2 Years 1

Overview of Studies

Interventional Trials

#If less then 500 trials

nct_id brief_title link overall_status source primary_completion_date
NCT03828448 Study to Assess Umbralisib Plus Ublituximab in Patients With Treatment Naïve Follicular Lymphoma https://ClinicalTrials.gov/show/NCT03828448 Recruiting TG Therapeutics, Inc. 2022-02-28
NCT03789240 Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma https://ClinicalTrials.gov/show/NCT03789240 Recruiting National Institutes of Health Clinical Center (CC) 2027-01-01
NCT03768505 ME-401 in Subjects With Follicular Lymphoma After Failure of Two or More Prior Therapies (TIDAL) https://ClinicalTrials.gov/show/NCT03768505 Recruiting MEI Pharma, Inc. 2020-12-31
NCT03410901 TLR9 Agonist SD-101, Anti-OX40 Antibody BMS 986178, and Radiation Therapy in Treating Patients With Low-Grade B-Cell Non-Hodgkin Lymphomas https://ClinicalTrials.gov/show/NCT03410901 Recruiting Stanford University 2020-10-09
NCT03401853 Rituximab and Pembrolizumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma https://ClinicalTrials.gov/show/NCT03401853 Recruiting University of Washington 2021-02-15
NCT03381768 Peptide Vaccination Against PD-L1 and PD-L2 in Relapsed Follicular Lymphoma https://ClinicalTrials.gov/show/NCT03381768 Active, not recruiting Herlev Hospital 2020-12-31
NCT03341520 Gazyvaro and Low Dose Radiotherapy in Early Stage Follicular Lymphoma https://ClinicalTrials.gov/show/NCT03341520 Recruiting Heidelberg University 2021-06-30
NCT03310619 A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies (PLATFORM) https://ClinicalTrials.gov/show/NCT03310619 Recruiting Celgene 2023-04-11
NCT03297424 A Study of PLX2853 in Advanced Malignancies. https://ClinicalTrials.gov/show/NCT03297424 Recruiting Plexxikon 2020-12-31
NCT03277729 A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas https://ClinicalTrials.gov/show/NCT03277729 Recruiting Fred Hutchinson Cancer Research Center 2022-11-16
NCT03245021 Nivolumab Plus Rituximab in First-line Follicular Lymphoma gr 1-3A https://ClinicalTrials.gov/show/NCT03245021 Recruiting Austin Health 2022-06-30
NCT03238651 A Study of TAK-659 as a Single Agent in Adult East Asian Participants With Non-Hodgkin Lymphoma (NHL) https://ClinicalTrials.gov/show/NCT03238651 Active, not recruiting Takeda 2020-10-09
NCT03185494 Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD22 https://ClinicalTrials.gov/show/NCT03185494 Active, not recruiting Chinese PLA General Hospital 2019-08-01
NCT03178201 TGR1202 in Relapsed and Refractory Follicular Lymphoma https://ClinicalTrials.gov/show/NCT03178201 Recruiting Columbia University 2020-05-31
NCT03269669 Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma https://ClinicalTrials.gov/show/NCT03269669 Recruiting National Cancer Institute (NCI) 2022-12-31
NCT03162536 A Study of ARQ 531 in Patients With Selected Hematologic Malignancies https://ClinicalTrials.gov/show/NCT03162536 Recruiting ArQule 2021-12-31
NCT03150329 Pembrolizumab and Vorinostat in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, or Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT03150329 Recruiting City of Hope Medical Center 2020-07-18
NCT03147885 Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT03147885 Recruiting Barbara Ann Karmanos Cancer Institute 2020-06-30
NCT03126019 An Open-Label Study of INCB050465 in Relapsed or Refractory Follicular Lymphoma (CITADEL-203) https://ClinicalTrials.gov/show/NCT03126019 Recruiting Incyte Corporation 2020-10-31
NCT03121677 Personalized Tumor Vaccine Strategy and PD-1 Blockade in Patients With Follicular Lymphoma https://ClinicalTrials.gov/show/NCT03121677 Recruiting Washington University School of Medicine 2022-07-31
NCT03113422 Phase II Venetoclax, Obinutuzumab and Bendamustine in High Tumor Burden Follicular Lymphoma as Front Line Therapy https://ClinicalTrials.gov/show/NCT03113422 Recruiting PrECOG, LLC. 2022-04-30
NCT03097770 Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20 https://ClinicalTrials.gov/show/NCT03097770 Recruiting Chinese PLA General Hospital 2019-05-10
NCT03069248 Treatment of Follicular Lymphoma With High Dose Therapy and Stem Cell Support Followed by Rituximab and Alpha Interferon https://ClinicalTrials.gov/show/NCT03069248 Completed Sunnybrook Health Sciences Centre 2009-09-17
NCT03057418 Open-label Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AuriÑ…im https://ClinicalTrials.gov/show/NCT03057418 Completed Biointegrator LLC 2016-12-31
NCT03039114 Study Evaluating Safety and Efficacy of INCB050465 Combined With Bendamustine and Obinutuzumab in Relapsed or Refractory Follicular Lymphoma (CITADEL-102) https://ClinicalTrials.gov/show/NCT03039114 Active, not recruiting Incyte Corporation 2021-09-30
NCT03037645 Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid Cancers https://ClinicalTrials.gov/show/NCT03037645 Recruiting Sunesis Pharmaceuticals 2020-12-31
NCT03019640 Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT03019640 Recruiting M.D. Anderson Cancer Center 2020-03-31
NCT03015896 Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT03015896 Recruiting Ohio State University Comprehensive Cancer Center 2020-04-30
NCT03010358 Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT03010358 Active, not recruiting OHSU Knight Cancer Institute 2022-02-28
NCT02996773 Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine https://ClinicalTrials.gov/show/NCT02996773 Recruiting University of Arizona 2022-11-29
NCT02950220 Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT02950220 Completed Ohio State University Comprehensive Cancer Center 2018-11-19
NCT02947347 Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma https://ClinicalTrials.gov/show/NCT02947347 Recruiting Pharmacyclics LLC. 2022-01-31
NCT02877550 Obinutuzumab in Combination With Venetoclax in Previously Untreated Follicular Lymphoma Patients https://ClinicalTrials.gov/show/NCT02877550 Active, not recruiting Swiss Group for Clinical Cancer Research 2021-06-30
NCT02871219 Obinutuzumab and Lenalidomide in Treating Patients With Previously Untreated Stage II-IV Grade 1-3a Follicular Lymphoma https://ClinicalTrials.gov/show/NCT02871219 Active, not recruiting M.D. Anderson Cancer Center 2023-07-23
NCT02869633 Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant https://ClinicalTrials.gov/show/NCT02869633 Active, not recruiting Vanderbilt-Ingram Cancer Center 2021-10-31
NCT02797470 Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant https://ClinicalTrials.gov/show/NCT02797470 Recruiting AIDS Malignancy Consortium 2021-09-30
NCT02756247 A Clinical Trial of Buparlisib and Ibrutinib in Lymphoma https://ClinicalTrials.gov/show/NCT02756247 Active, not recruiting Memorial Sloan Kettering Cancer Center 2021-05-31
NCT02729896 A Study Evaluating Safety and Efficacy of Obinutuzumab, Polatuzumab Vedotin (Pola), and Atezolizumab (Atezo) in Participants With Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab, Atezo, and Pola in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) https://ClinicalTrials.gov/show/NCT02729896 Completed Hoffmann-La Roche 2018-09-03
NCT02723071 A Study of Ocrelizumab in Participants With Follicular Non-Hodgkin’s Lymphoma (NHL) https://ClinicalTrials.gov/show/NCT02723071 Completed Hoffmann-La Roche 2008-01-31
NCT02710643 “MIRO” Molecularly Oriented Immuno-radio-therapy https://ClinicalTrials.gov/show/NCT02710643 Active, not recruiting Fondazione Italiana Linfomi ONLUS 2018-04-30
NCT02689869 Combination of PCI-32765 With Obinutuzumab in Untreated Follicular Lymphoma https://ClinicalTrials.gov/show/NCT02689869 Active, not recruiting Ludwig-Maximilians - University of Munich 2022-04-30
NCT02677155 Sequential Intranodal Immunotherapy (SIIT) Combined With Anti-PD1 (Pembrolizumab) in Follicular Lymphoma https://ClinicalTrials.gov/show/NCT02677155 Recruiting Oslo University Hospital 2020-01-31
NCT02669017 Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL) https://ClinicalTrials.gov/show/NCT02669017 Completed ADC Therapeutics S.A. 2019-02-21
NCT02652715 Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT02652715 Completed Mayo Clinic 2018-12-21
NCT02631577 A Study Evaluating the Safety and Efficacy of Atezolizumab in Combination With Obinutuzumab Plus Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma https://ClinicalTrials.gov/show/NCT02631577 Active, not recruiting Hoffmann-La Roche 2018-10-23
NCT02611323 A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL) https://ClinicalTrials.gov/show/NCT02611323 Active, not recruiting Hoffmann-La Roche 2020-09-08
NCT02603445 Study of Safety and Efficacy of BCL201 and Idelalisib in Patients With FL and MCL https://ClinicalTrials.gov/show/NCT02603445 Completed Novartis 2018-07-10
NCT02600897 A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) https://ClinicalTrials.gov/show/NCT02600897 Active, not recruiting Hoffmann-La Roche 2020-10-05
NCT02596971 A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) https://ClinicalTrials.gov/show/NCT02596971 Active, not recruiting Hoffmann-La Roche 2018-04-11
NCT03357627 A Study of TAK-659 in Combination With Venetoclax for Adult Participants With Previously Treated Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT03357627 Active, not recruiting Takeda 2020-10-28
NCT02956382 Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma https://ClinicalTrials.gov/show/NCT02956382 Recruiting Georgetown University 2020-11-30
NCT02927964 TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular Lymphoma https://ClinicalTrials.gov/show/NCT02927964 Recruiting Stanford University 2021-11-30
NCT02376699 Safety Study of SEA-CD40 in Cancer Patients https://ClinicalTrials.gov/show/NCT02376699 Recruiting Seattle Genetics, Inc. 2021-10-31
NCT02569996 A Study of Long-Term Rituximab (MabThera) Maintenance Therapy in Participants With Advanced Follicular Lymphoma https://ClinicalTrials.gov/show/NCT02569996 Completed Hoffmann-La Roche 2013-08-31
NCT02568553 Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT02568553 Recruiting National Cancer Institute (NCI) 2020-12-31
NCT01381692 Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma https://ClinicalTrials.gov/show/NCT01381692 Active, not recruiting National Cancer Institute (NCI) 2014-07-23
NCT02541565 Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Diffuse Large B-cell Lymphoma or Grade 3b Follicular Lymphoma https://ClinicalTrials.gov/show/NCT02541565 Completed University of Washington 2018-12-18
NCT02536300 Dose Optimization Study of Idelalisib in Follicular Lymphoma https://ClinicalTrials.gov/show/NCT02536300 Recruiting Gilead Sciences 2025-11-30
NCT02532257 Ibrutinib in Combination With Rituximab and Lenalidomide in Treating Patients With Previously Untreated, Stage II-IV Follicular Lymphoma or Marginal Zone Lymphoma https://ClinicalTrials.gov/show/NCT02532257 Active, not recruiting M.D. Anderson Cancer Center 2020-04-01
NCT02520791 Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell Lymphoma https://ClinicalTrials.gov/show/NCT02520791 Recruiting National Cancer Institute (NCI) 2020-12-31
NCT02494700 Ultra Low Dose Orbital Radiation Therapy in Treating Patients With Stage I-IV Indolent B-cell Lymphoma or Mantle Cell Lymphoma https://ClinicalTrials.gov/show/NCT02494700 Recruiting M.D. Anderson Cancer Center 2021-10-31
NCT02449252 Efficacy of Consolidative Involved-site Radiotherapy for Patients With Limited-stage Follicular Lymphoma https://ClinicalTrials.gov/show/NCT02449252 Recruiting Wuhan University 2019-10-31
NCT02446457 Rituximab and Pembrolizumab With or Without Lenalidomide in Treating Patients With Relapsed Follicular Lymphoma and Diffuse Large B-Cell Lymphoma https://ClinicalTrials.gov/show/NCT02446457 Recruiting M.D. Anderson Cancer Center 2021-11-01
NCT02438501 Efficacy of Palliative Low-Dose Involved-Field Radiation Therapy for Recurrent Advanced Follicular Lymphoma https://ClinicalTrials.gov/show/NCT02438501 Recruiting Wuhan University 2019-10-31
NCT02432235 Study of ADCT-301 in Patients With Relapsed or Refractory Hodgkin and Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT02432235 Completed ADC Therapeutics S.A. 2019-10-24
NCT02423837 Bendamustine in Combination With Rituximab as a First-line Therapy Followed by Maintenance Therapy With Rituximab in Patients With Follicular Lymphoma https://ClinicalTrials.gov/show/NCT02423837 Recruiting National Research Center for Hematology, Russia 2016-02-29
NCT02390869 Rituximab and Lenalidomide vs Rituximab Alone as Maintenance After R-chemoterapy for Relapsed/Refractory FL Patients https://ClinicalTrials.gov/show/NCT02390869 Recruiting Fondazione Italiana Linfomi ONLUS 2022-12-31
NCT02343536 A Phase 1, Open-label Trial of Oral Azacitidine (CC-486) Plus RCHOP in Subjects With Large B-Cell Lymphoma or Follicular Lymphoma or Transformed Lymphoma https://ClinicalTrials.gov/show/NCT02343536 Active, not recruiting Celgene 2020-02-01
NCT02332980 Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas https://ClinicalTrials.gov/show/NCT02332980 Recruiting Mayo Clinic 2021-01-05
NCT02320292 Rituximab With or Without Yttrium Y-90 Ibritumomab Tiuxetan in Treating Patients With Untreated Follicular Lymphoma https://ClinicalTrials.gov/show/NCT02320292 Recruiting Mayo Clinic 2020-06-01
NCT02303119 Follicular Lymphoma IV/SC Rituximab Therapy (FLIRT) https://ClinicalTrials.gov/show/NCT02303119 Active, not recruiting The Lymphoma Academic Research Organisation 2020-06-30
NCT02282358 Study of Mocetinostat in Selected Patients With Mutations of Acetyltransferase Genes in Relapsed and Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma https://ClinicalTrials.gov/show/NCT02282358 Active, not recruiting Memorial Sloan Kettering Cancer Center 2021-10-31
NCT02257242 Vincristine Sulfate Liposome Injection (Marqibo®), Bendamustine and Rituximab—Phase I Trial in Indolent B-cell Lymphoma https://ClinicalTrials.gov/show/NCT02257242 Recruiting Brown University 2020-12-31
NCT02254772 A Phase I/II Study of Intratumoral Injection of SD-101 https://ClinicalTrials.gov/show/NCT02254772 Completed Stanford University 2016-11-10
NCT02240719 Everolimus and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Hematologic Cancer https://ClinicalTrials.gov/show/NCT02240719 Completed University of California, Davis 2018-04-09
NCT02220842 A Safety and Pharmacology Study of Atezolizumab (MPDL3280A) Administered With Obinutuzumab or Tazemetostat in Participants With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma https://ClinicalTrials.gov/show/NCT02220842 Completed Hoffmann-La Roche 2020-01-21
NCT02216890 Safety Study of SGN-CD70A in Cancer Patients https://ClinicalTrials.gov/show/NCT02216890 Completed Seattle Genetics, Inc. 2017-02-15
NCT02213913 Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas https://ClinicalTrials.gov/show/NCT02213913 Recruiting University of Chicago 2020-07-29
NCT02213263 A Study Of PF-05280586 (Rituximab-Pfizer) Or MabThera® (Rituximab-EU) For The First-Line Treatment Of Patients With CD20-Positive, Low Tumor Burden, Follicular Lymphoma (REFLECTIONS B328-06) https://ClinicalTrials.gov/show/NCT02213263 Completed Pfizer 2017-10-23
NCT02208037 Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203) https://ClinicalTrials.gov/show/NCT02208037 Completed National Heart, Lung, and Blood Institute (NHLBI) 2017-10-31
NCT02187861 A Study Evaluating the Safety and Efficacy of Venetoclax (GDC-0199) Plus Bendamustine + Rituximab (BR) in Comparison With BR or Venetoclax Plus Rituximab in Participants With Relapsed and Refractory Follicular Non-Hodgkin’s Lymphoma (fNHL) https://ClinicalTrials.gov/show/NCT02187861 Completed Hoffmann-La Roche 2016-09-27
NCT02162771 To Demonstrate Equivalence of Pharmacokinetics and Noninferiority of Efficacy for CT-P10 in Comparison With Rituxan https://ClinicalTrials.gov/show/NCT02162771 Completed Celltrion 2016-01-12
NCT02153580 Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia or B-Cell Prolymphocytic Leukemia https://ClinicalTrials.gov/show/NCT02153580 Recruiting City of Hope Medical Center 2021-12-31
NCT02063685 Study to Evaluate the Efficacy of Response-adapted Strategy in Follicular Lymphoma https://ClinicalTrials.gov/show/NCT02063685 Active, not recruiting Fondazione Italiana Linfomi ONLUS 2021-12-31
NCT01307605 Rituximab With or Without Lenalidomide in Treating Patients With Previously Untreated Follicular Lymphoma https://ClinicalTrials.gov/show/NCT01307605 Active, not recruiting Swiss Group for Clinical Cancer Research 2014-06-20
NCT01307267 A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab https://ClinicalTrials.gov/show/NCT01307267 Completed Pfizer 2019-02-20
NCT01306643 Safety and Efficacy Study of Idelalisib (GS-1101, CAL-101) in Patients With Previously Treated Low-grade Lymphoma https://ClinicalTrials.gov/show/NCT01306643 Completed Gilead Sciences 2015-08-31
NCT01286272 Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT01286272 Active, not recruiting National Cancer Institute (NCI) 2017-05-24
NCT01282424 Efficacy and Safety Study of Idelalisib in Participants With Indolent B-Cell Non-Hodgkin Lymphomas https://ClinicalTrials.gov/show/NCT01282424 Completed Gilead Sciences 2018-05-02
NCT01275209 Study of HCD122 (Lucatumumab) and Bendamustine Combination Therapy in CD40+ Rituximab-refractory Follicular Lymphoma https://ClinicalTrials.gov/show/NCT01275209 Completed Novartis 2012-05-31
NCT01273766 Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies https://ClinicalTrials.gov/show/NCT01273766 Completed Wake Forest University Health Sciences 2012-03-31
NCT02049541 Study of BKM120 & Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma https://ClinicalTrials.gov/show/NCT02049541 Active, not recruiting Ohio State University Comprehensive Cancer Center 2018-09-12
NCT02038946 Study of Nivolumab in Subjects With Relapsed or Refractory Follicular Lymphoma (FL) (CheckMate 140) https://ClinicalTrials.gov/show/NCT02038946 Active, not recruiting Bristol-Myers Squibb 2017-05-17
NCT02031419 Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma and Follicular Lymphoma https://ClinicalTrials.gov/show/NCT02031419 Active, not recruiting Celgene 2020-11-30
NCT04324879 A Study of TQ-B3525 in the Treatment of Relapsed / Refractory Follicular Lymphoma (FL) https://ClinicalTrials.gov/show/NCT04324879 Recruiting Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 2022-12-31
NCT03479268 Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT03479268 Recruiting City of Hope Medical Center 2022-04-01
NCT02012088 Clinical Trial to Evaluate R-COMP Versus R-CHOP in Newly Diagnosed Patients With Non-localised Diffuse Large B-cell Lymphoma (DLBCL)/Follicular Lymphoma Grade IIIb https://ClinicalTrials.gov/show/NCT02012088 Active, not recruiting Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea 2016-10-31
NCT01995669 Lenalidomide and Obinutuzumab in Treating Patients With Relapsed Indolent Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT01995669 Active, not recruiting M.D. Anderson Cancer Center 2021-05-31
NCT01980654 Study of Ibrutinib in Combination With Rituximab in Previously Untreated Subjects With Follicular Lymphoma https://ClinicalTrials.gov/show/NCT01980654 Completed Pharmacyclics LLC. 2017-11-30
NCT01962636 Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases https://ClinicalTrials.gov/show/NCT01962636 Recruiting Masonic Cancer Center, University of Minnesota 2023-10-31
NCT01959477 Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Cell Transplant https://ClinicalTrials.gov/show/NCT01959477 Completed Case Comprehensive Cancer Center 2015-01-31
NCT01955499 Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT01955499 Active, not recruiting National Cancer Institute (NCI) 2021-12-31
NCT01950273 Pharmacokinetics and Pharmacodynamics of BI 695500 vs. Rituximab as First Line-treatment in Patients With Low Tumor Burden Follicular Lymphoma https://ClinicalTrials.gov/show/NCT01950273 Completed Boehringer Ingelheim 2015-12-22
NCT01939899 Phase 2 Study of Oral IXAZOMIB in Adult Participants With Relapsed and/or Refractory Follicular Lymphoma https://ClinicalTrials.gov/show/NCT01939899 Completed Takeda 2016-06-01
NCT01926639 Phase II Cancer Vaccine Trial for Patients With Follicular Lymphoma https://ClinicalTrials.gov/show/NCT01926639 Completed Oslo University Hospital 2014-10-31
NCT01897571 Open-Label, Multicenter, Phase 1/2 Study of Tazemetostat (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Adv. Solid Tumors or With B-cell Lymphomas and Tazemetostat in Combination With Prednisolone in Subjects With DLBCL https://ClinicalTrials.gov/show/NCT01897571 Active, not recruiting Epizyme, Inc. 2019-11-30
NCT01897012 Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas https://ClinicalTrials.gov/show/NCT01897012 Completed National Cancer Institute (NCI) 2018-10-31
NCT01889069 A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Rituximab (MabThera/Rituxan) in Participants With Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL) https://ClinicalTrials.gov/show/NCT01889069 Completed Hoffmann-La Roche 2019-05-28
NCT01839916 Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies https://ClinicalTrials.gov/show/NCT01839916 Completed University of Chicago 2018-08-31
NCT01830465 VELCADE® Plus Rituximab in Non Hodgkin’s Follicular Lymphoma https://ClinicalTrials.gov/show/NCT01830465 Completed Gruppo Italiano Studio Linfomi 2008-08-31
NCT01829568 Rituximab, Lenalidomide, and Ibrutinib in Treating Patients With Previously Untreated Stage II-IV Follicular Lymphoma https://ClinicalTrials.gov/show/NCT01829568 Active, not recruiting National Cancer Institute (NCI) 2015-05-11
NCT01827605 A Phase III Multicenter, Randomized Study Comparing RIT Vs ASCT in Patients With Relapsed/Refractory (FL) https://ClinicalTrials.gov/show/NCT01827605 Active, not recruiting Fondazione Italiana Linfomi ONLUS 2020-06-30
NCT01815749 Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT01815749 Active, not recruiting City of Hope Medical Center 2020-10-31
NCT01805037 Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas https://ClinicalTrials.gov/show/NCT01805037 Active, not recruiting Northwestern University 2021-01-31
NCT01804686 A Long-term Extension Study of PCI-32765 (Ibrutinib) https://ClinicalTrials.gov/show/NCT01804686 Enrolling by invitation Janssen Research & Development, LLC 2026-12-31
NCT01789255 Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies https://ClinicalTrials.gov/show/NCT01789255 Completed National Cancer Institute (NCI) 2014-03-31
NCT01786135 A Safety Study of SGN-CD19A for B-Cell Lymphoma https://ClinicalTrials.gov/show/NCT01786135 Completed Seattle Genetics, Inc. 2015-08-31
NCT01779791 A Study of PCI-32765 (Ibrutinib) in Patients With Refractory Follicular Lymphoma https://ClinicalTrials.gov/show/NCT01779791 Completed Janssen Research & Development, LLC 2016-05-18
NCT01760655 Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies https://ClinicalTrials.gov/show/NCT01760655 Recruiting Thomas Jefferson University 2021-03-31
NCT01748721 MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma https://ClinicalTrials.gov/show/NCT01748721 Completed Morphotek 2015-05-31
NCT01724021 A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin’s Lymphoma Grades 1, 2 or 3a https://ClinicalTrials.gov/show/NCT01724021 Completed Hoffmann-La Roche 2015-01-31
NCT01701232 Safety and Efficacy Study of BCD-020 in Therapy of Indolent Non-Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT01701232 Completed Biocad 2017-01-31
NCT01693614 Safety and Efficacy of BKM120 in Relapsed and Refractory NHL https://ClinicalTrials.gov/show/NCT01693614 Completed Novartis 2017-07-21
NCT01682044 Pegfilgrastim and Rituximab in Treating Patients With Untreated, Relapsed, or Refractory Follicular Lymphoma, Small Lymphocytic Lymphoma, or Marginal Zone Lymphoma https://ClinicalTrials.gov/show/NCT01682044 Completed Roswell Park Cancer Institute 2013-11-22
NCT01680991 A Study of Obinutuzumab in Chinese Participants With CD20+ Malignant Disease https://ClinicalTrials.gov/show/NCT01680991 Completed Hoffmann-La Roche 2014-12-31
NCT01678443 Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies https://ClinicalTrials.gov/show/NCT01678443 Active, not recruiting Fred Hutchinson Cancer Research Center 2011-04-11
NCT01658319 Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies https://ClinicalTrials.gov/show/NCT01658319 Completed Case Comprehensive Cancer Center 2015-02-28
NCT01650701 A Phase 3 Open Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy Followed by Rituximab in Subjects With Previously Untreated Follicular Lymphoma https://ClinicalTrials.gov/show/NCT01650701 Active, not recruiting The Lymphoma Academic Research Organisation 2023-12-31
NCT01644799 Lenalidomide and Idelalisib in Treating Patients With Recurrent Follicular Lymphoma https://ClinicalTrials.gov/show/NCT01644799 Completed Alliance for Clinical Trials in Oncology 2014-08-31
NCT01588015 Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant https://ClinicalTrials.gov/show/NCT01588015 Active, not recruiting City of Hope Medical Center 2021-11-30
NCT01567709 Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma https://ClinicalTrials.gov/show/NCT01567709 Completed National Cancer Institute (NCI) 2018-03-29
NCT01529827 Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies https://ClinicalTrials.gov/show/NCT01529827 Completed Roswell Park Cancer Institute 2015-05-28
NCT01523860 Brief Chemoimmunotherapy With R+B+M Followed by R in Elderly Patients Advanced Stage Untreated Follicular Lymphoma https://ClinicalTrials.gov/show/NCT01523860 Completed Fondazione Italiana Linfomi ONLUS 2015-01-31
NCT01523223 Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies https://ClinicalTrials.gov/show/NCT01523223 Completed Stanford University 2016-09-30
NCT01493479 Phase II Study of Fractionated 90Y Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy as an Initial Therapy of Follicular Lymphoma https://ClinicalTrials.gov/show/NCT01493479 Completed The Christie NHS Foundation Trust 2011-01-31
NCT01484015 Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia https://ClinicalTrials.gov/show/NCT01484015 Completed Wake Forest University Health Sciences 2012-06-30
NCT01479842 Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT01479842 Active, not recruiting Ohio State University Comprehensive Cancer Center 2014-03-31
NCT01473628 Radiation Therapy and Rituximab in Treating Patients With Stage I-II Grade 1 or Grade 2 Follicular Lymphoma https://ClinicalTrials.gov/show/NCT01473628 Recruiting M.D. Anderson Cancer Center 2027-05-20
NCT01446562 Y90 Ibritumomab Tiuxetan Post R-CHOP Chemotherapy for Advanced Stage Follicular Lymphoma https://ClinicalTrials.gov/show/NCT01446562 Completed Sunnybrook Health Sciences Centre 2016-05-31
NCT01419665 GP2013 in the Treatment of Patients With Previously Untreated, Advanced Stage Follicular Lymphoma https://ClinicalTrials.gov/show/NCT01419665 Completed Sandoz 2015-07-10
NCT01393756 Revlimid Dose 25 mg in Association With (R-CHOP) in the Treatment Follicular Lymphoma https://ClinicalTrials.gov/show/NCT01393756 Completed The Lymphoma Academic Research Organisation 2013-07-31
NCT01392716 A Study of MabThera/Rituxan (Rituximab) in Patients With Non-Bulky Follicular Non-Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT01392716 Completed Hoffmann-La Roche 2006-02-28
NCT01388959 A Study of MabThera/Rituxan (Rituximab) in Patients With Follicular Non-Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT01388959 Completed Hoffmann-La Roche 2004-04-30
NCT01384513 A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies https://ClinicalTrials.gov/show/NCT01384513 Recruiting Thomas Jefferson University 2020-12-31
NCT01326702 Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors https://ClinicalTrials.gov/show/NCT01326702 Completed National Cancer Institute (NCI) 2015-04-30
NCT01321541 Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant https://ClinicalTrials.gov/show/NCT01321541 Completed CTI BioPharma 2018-06-28
NCT04370405 A Study of YY-20394 in Participants With Relapsed/Refractory Follicular Non-Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT04370405 Recruiting Shanghai YingLi Pharmaceutical Co. Ltd. 2020-11-30
NCT04323956 Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma https://ClinicalTrials.gov/show/NCT04323956 Recruiting Mayo Clinic 2026-05-15
NCT04305444 Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin’s Lymphomas https://ClinicalTrials.gov/show/NCT04305444 Recruiting Zhejiang DTRM Biopharma 2022-03-31
NCT04298879 IBI376 in Relapsed or Refractory Follicular Lymphoma/Marginal Zone Lymphoma https://ClinicalTrials.gov/show/NCT04298879 Recruiting Innovent Biologics (Suzhou) Co. Ltd. 2021-07-31
NCT04205838 Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients With Recurrent or Refractory Large B-cell Lymphoma https://ClinicalTrials.gov/show/NCT04205838 Recruiting Jonsson Comprehensive Cancer Center 2021-12-01
NCT04205409 Nivolumab for Relapsed or Refractory Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies https://ClinicalTrials.gov/show/NCT04205409 Recruiting University of Washington 2022-08-01
NCT04156828 Copanlisib and Combination Chemotherapy for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Relapsed Grade 3b Follicular Lymphoma https://ClinicalTrials.gov/show/NCT04156828 Recruiting University of Washington 2022-07-31
NCT04097067 ISRT 20 Gy for Indolent Localized Gastrointestinal (GI)-Lymphoma https://ClinicalTrials.gov/show/NCT04097067 Recruiting University Hospital Muenster 2021-08-31
NCT04082936 A Safety and Pharmacokinetic Study of IGM-2323 in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT04082936 Recruiting IGM Biosciences, Inc. 2021-09-30
NCT04049513 ENABLE (Engaging Toll-like Receptor Signalling for B-cell Lymphoma Chimeric Antigen Receptor Therapy) https://ClinicalTrials.gov/show/NCT04049513 Recruiting Malaghan Institute of Medical Research 2021-09-30
NCT04007029 Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia https://ClinicalTrials.gov/show/NCT04007029 Recruiting Jonsson Comprehensive Cancer Center 2022-08-01
NCT03999697 A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies https://ClinicalTrials.gov/show/NCT03999697 Recruiting PersonGen BioTherapeutics (Suzhou) Co., Ltd. 2020-12-01
NCT03980171 Study of Lenalidomide, Venetoclax and Obinutuzumab in Patients With Treatment-Naïve Follicular Lymphoma https://ClinicalTrials.gov/show/NCT03980171 Recruiting Peter MacCallum Cancer Centre, Australia 2026-11-30
NCT03939026 Safety and Efficacy of ALLO-501 Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell or Follicular Lymphoma https://ClinicalTrials.gov/show/NCT03939026 Recruiting Allogene Therapeutics 2021-10-31
NCT03934567 A Multi-Center Phase 2 Study to Evaluate Efficacy and Safety of Oral Abexinostat as Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma https://ClinicalTrials.gov/show/NCT03934567 Recruiting Xynomic Pharmaceuticals, Inc. 2023-06-30
NCT03921879 Safety and Efficacy of OT-82 in Participants With Relapsed or Refractory Lymphoma https://ClinicalTrials.gov/show/NCT03921879 Recruiting Oncotartis, Inc. 2021-04-30
NCT03919175 Umbralisib and Rituximab as Initial Therapy for Patients With Follicular Lymphoma and Marginal Zone Lymphoma https://ClinicalTrials.gov/show/NCT03919175 Recruiting Massachusetts General Hospital 2022-11-30
NCT03892044 Duvelisib and Nivolumab in Treating Patients With Richter Syndrome or Transformed Follicular Lymphoma https://ClinicalTrials.gov/show/NCT03892044 Recruiting Ohio State University Comprehensive Cancer Center 2021-12-31
NCT03817853 An Open-Label, Single Arm Study of Obinutuzumab Short Duration Infusion in Patients With Previously Untreated Advanced Follicular Lymphoma https://ClinicalTrials.gov/show/NCT03817853 Recruiting Hoffmann-La Roche 2020-07-20
NCT03806179 Study of Safety and Efficacy of Betalutin and Rituximab in Patients With FL https://ClinicalTrials.gov/show/NCT03806179 Recruiting Nordic Nanovector 2020-09-30
NCT03720457 Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory CD19-positive Lymphoma. https://ClinicalTrials.gov/show/NCT03720457 Recruiting Hrain Biotechnology Co., Ltd. 2021-10-31
NCT03715309 R2 in the Treatment of Follicular Lymphoma https://ClinicalTrials.gov/show/NCT03715309 Recruiting Ruijin Hospital 2020-11-01
NCT03685344 Safety and Antitumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular Lymphoma https://ClinicalTrials.gov/show/NCT03685344 Active, not recruiting ADC Therapeutics S.A. 2021-01-29
NCT03682796 Study of TRPH-222 in Patients With Relapsed and/or Refractory B-Cell Lymphoma https://ClinicalTrials.gov/show/NCT03682796 Recruiting Triphase Research and Development III Corp. 2022-01-31
NCT03636503 RITUXIMAB + IMMUNOTHERAPY IN FOLLICULAR LYMPHOMA https://ClinicalTrials.gov/show/NCT03636503 Recruiting Dana-Farber Cancer Institute 2021-10-30
NCT03610061 A Trial of Radiotherapy and Durvalumab in DLBCL and FL https://ClinicalTrials.gov/show/NCT03610061 Recruiting Austin Health 2021-02-28
NCT03600441 Study of Abexinostat in Patients With Relapsed or Refractory Follicular Lymphoma https://ClinicalTrials.gov/show/NCT03600441 Active, not recruiting Xynomic Pharmaceuticals, Inc. 2020-09-01
NCT03600363 A Clinical Trial of Metformin in the Maintenance of Non-Hodgkin’s Lymphoma Patients https://ClinicalTrials.gov/show/NCT03600363 Recruiting Ruijin Hospital 2021-01-31
NCT03598998 Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas https://ClinicalTrials.gov/show/NCT03598998 Recruiting City of Hope Medical Center 2021-04-27
NCT03583424 Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT03583424 Recruiting Ohio State University Comprehensive Cancer Center 2021-12-31
NCT03571828 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 562 in Subjects With r/r Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, or Follicular Lymphoma https://ClinicalTrials.gov/show/NCT03571828 Recruiting Amgen 2023-06-30
NCT03568461 Efficacy and Safety of Tisagenlecleucel in Adult Patients With Refractory or Relapsed Follicular Lymphoma https://ClinicalTrials.gov/show/NCT03568461 Active, not recruiting Novartis 2021-02-22
NCT01261247 Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT01261247 Active, not recruiting Mayo Clinic 2016-05-09
NCT01258998 Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma https://ClinicalTrials.gov/show/NCT01258998 Completed National Cancer Institute (NCI) 2014-07-31
NCT01254578 Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers https://ClinicalTrials.gov/show/NCT01254578 Completed National Cancer Institute (NCI) 2012-11-09
NCT01239875 Vaccine Therapy With or Without Cryosurgery in Treating Patients With Residual, Relapsed, or Refractory B-Cell Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT01239875 Completed Mayo Clinic 2015-11-24
NCT01234766 Bendamustine and Rituximab Followed by 90-yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular Lymphoma https://ClinicalTrials.gov/show/NCT01234766 Active, not recruiting Dartmouth-Hitchcock Medical Center 2014-06-30
NCT01233921 Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer https://ClinicalTrials.gov/show/NCT01233921 Completed Fred Hutchinson Cancer Research Center 2012-07-31
NCT01231919 MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia https://ClinicalTrials.gov/show/NCT01231919 Completed National Cancer Institute (NCI) 2013-04-30
NCT01216683 Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma https://ClinicalTrials.gov/show/NCT01216683 Active, not recruiting Eastern Cooperative Oncology Group 2020-06-01
NCT01193842 Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas https://ClinicalTrials.gov/show/NCT01193842 Active, not recruiting National Cancer Institute (NCI) 2016-11-12
NCT01190449 Ofatumumab in Treating Patients With Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT01190449 Active, not recruiting Alliance for Clinical Trials in Oncology 2015-03-31
NCT01177371 High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT01177371 Completed Case Comprehensive Cancer Center 2000-02-29
NCT01158274 RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors https://ClinicalTrials.gov/show/NCT01158274 Completed National Cancer Institute (NCI) 2012-08-31
NCT01145495 Lenalidomide and Rituximab in Treating Patients With Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT01145495 Active, not recruiting National Cancer Institute (NCI) 2012-12-31
NCT01130194 Immunochemotherapy, Zevalin, and Bone Marrow Transplant for Follicular Lymphoma https://ClinicalTrials.gov/show/NCT01130194 Completed St. Louis University 2012-06-30
NCT01129193 AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma https://ClinicalTrials.gov/show/NCT01129193 Completed Ohio State University Comprehensive Cancer Center 2017-01-07
NCT01110135 Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma https://ClinicalTrials.gov/show/NCT01110135 Completed University of Washington 2013-11-30
NCT01093586 Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies https://ClinicalTrials.gov/show/NCT01093586 Completed Case Comprehensive Cancer Center 2015-12-31
NCT01078142 Temsirolimus, Bendamustine and Rituximab for Relapsed Follicular Lymphoma or Mantle Cell Lymphoma https://ClinicalTrials.gov/show/NCT01078142 Completed Johannes Gutenberg University Mainz 2017-09-08
NCT01075321 Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT01075321 Active, not recruiting Mayo Clinic 2015-02-28
NCT01029366 CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to Chemotherapy https://ClinicalTrials.gov/show/NCT01029366 Completed University of Pennsylvania 2015-07-31
NCT01022255 Autologous Vaccine for Follicular Lymphoma https://ClinicalTrials.gov/show/NCT01022255 Completed Icon Genetics GmbH 2013-10-31
NCT00930514 A Pharmacokinetic Study of Subcutaneous and Intravenous Rituximab in Participants With Follicular Lymphoma https://ClinicalTrials.gov/show/NCT00930514 Completed Hoffmann-La Roche 2013-07-31
NCT00918333 Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT00918333 Completed Mayo Clinic 2015-12-01
NCT00912223 Blood Stem Cell Transplant With Low Dose Chemotherapy for Relapsed Follicular Non-Hodgkin’s Lymphoma (BMT CTN 0701) https://ClinicalTrials.gov/show/NCT00912223 Completed Medical College of Wisconsin 2014-11-30
NCT00904722 Monoclonal Antibody CT-011 in Combination With Rituximab in Patients With Relapsed Follicular Lymphoma https://ClinicalTrials.gov/show/NCT00904722 Completed M.D. Anderson Cancer Center 2015-04-30
NCT00891072 Gossypol, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery https://ClinicalTrials.gov/show/NCT00891072 Completed National Cancer Institute (NCI) 2011-04-30
NCT00890747 Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy https://ClinicalTrials.gov/show/NCT00890747 Completed National Cancer Institute (NCI) 2011-05-31
NCT00875056 Study of Vorinostat (MK0683) With Follicular Lymphoma (FL), Other Indolent B-cell Non-Hodgkin’s Lymphoma (B-NHL) or Mantle Cell Lymphoma (MCL) Patients (MK-0683-103) https://ClinicalTrials.gov/show/NCT00875056 Completed Merck Sharp & Dohme Corp. 2011-02-25
NCT00867529 Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma https://ClinicalTrials.gov/show/NCT00867529 Completed Fred Hutchinson Cancer Research Center 2015-03-31
NCT00864227 Evaluating the Safety and Effectiveness of an Umbilical Cord Blood Stem Cell Transplant (BMT CTN 0604) https://ClinicalTrials.gov/show/NCT00864227 Completed Medical College of Wisconsin 2011-04-30
NCT00856388 Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders https://ClinicalTrials.gov/show/NCT00856388 Completed Roswell Park Cancer Institute 2012-08-09
NCT00856245 Evaluate Rituximab in Obtaining PCR (Polymerase Chain Reaction) Negative Leukapheresis Product in Patients With Relapsed Follicular Lymphoma https://ClinicalTrials.gov/show/NCT00856245 Completed University of Kansas Medical Center 2015-07-31
NCT00849147 Bone Marrow Transplant From Partially Matched Donors and Nonmyeloablative Conditioning for Blood Cancers (BMT CTN 0603) https://ClinicalTrials.gov/show/NCT00849147 Completed Medical College of Wisconsin 2011-06-30
NCT02278796 A Trial Comparing the Two High-dose Chemotherapies BeEAM and BEAM Given Before Autologous Stem Cell Transplantation (ASCT) in Lymphoma Patients (BEB-trial) https://ClinicalTrials.gov/show/NCT02278796 Active, not recruiting University Hospital Inselspital, Berne 2018-11-28
NCT00825149 A Study of Obinutuzumab in Combination With Chemotherapy in Participants With CD20+ B-Cell Follicular Non-Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT00825149 Completed Hoffmann-La Roche 2015-11-30
NCT03585725 A Pilot Investigator-Initiated Study of Ribavirin in Indolent Follicular Lymphoma and Mantle Cell Lymphoma https://ClinicalTrials.gov/show/NCT03585725 Recruiting Weill Medical College of Cornell University 2020-06-30
NCT02809053 A Randomized, Double-blind, Multi-center, Multi-national Trial to Evaluate the Efficacy, Safety, and Immunogenicity of SAIT101 Versus Rituximab as a First-line Immunotherapy Treatment in Patients With Low Tumor Burden Follicular Lymphoma https://ClinicalTrials.gov/show/NCT02809053 Active, not recruiting Archigen Biotech Limited 2020-02-29
NCT01427881 Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies https://ClinicalTrials.gov/show/NCT01427881 Completed Fred Hutchinson Cancer Research Center 2014-06-30
NCT03460977 PF-06821497 Treatment Of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma https://ClinicalTrials.gov/show/NCT03460977 Recruiting Pfizer 2023-03-31
NCT03332017 A Study Comparing Obinutuzumab and BGB-3111 Versus Obinutuzumab Alone in Treating R/R Follicular Lymphoma https://ClinicalTrials.gov/show/NCT03332017 Recruiting BeiGene 2021-07-31
NCT02451111 Rituximab With or Without Ibrutinib for Patients With Advanced Follicular Lymphoma https://ClinicalTrials.gov/show/NCT02451111 Active, not recruiting Swiss Group for Clinical Cancer Research 2022-12-31
NCT01849263 Ibrutinib in Treating Patients With Relapsed or Refractory Follicular Lymphoma https://ClinicalTrials.gov/show/NCT01849263 Active, not recruiting National Cancer Institute (NCI) 2016-06-03
NCT00801281 First-line R-CVP vs R-CHOP Induction Immunochemotherapy for Indolent Lymphoma and R Maintenance. https://ClinicalTrials.gov/show/NCT00801281 Completed Polish Lymphoma Research Group 2017-06-25
NCT03210662 Pembrolizumab and External Beam Radiation Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT03210662 Recruiting M.D. Anderson Cancer Center 2020-11-30
NCT04224493 Study in Subjects With Relapsed/Refractory Follicular Lymphoma https://ClinicalTrials.gov/show/NCT04224493 Recruiting Epizyme, Inc. 2022-06-30
NCT03890289 Idelalisib+Obinutuzumab in Patients With Relapsed/Refractory Follicular Lymphoma https://ClinicalTrials.gov/show/NCT03890289 Recruiting Fondazione Italiana Linfomi ONLUS 2021-10-18
NCT02260804 To Compare Efficacy and Safety Between CT-P10 and Rituxan in Patients With Low Tumour Burden Follicular Lymphoma https://ClinicalTrials.gov/show/NCT02260804 Active, not recruiting Celltrion 2018-01-31
NCT01476787 Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma https://ClinicalTrials.gov/show/NCT01476787 Active, not recruiting Celgene 2024-06-01
NCT03976102 Compare the Efficacy, Safety, and Immunogenicity of Proposed Rituximab Biosimilar (DRL_RI) With MabThera® in LTB Follicular Lymphoma (FLINTER) https://ClinicalTrials.gov/show/NCT03976102 Recruiting Dr. Reddy’s Laboratories Limited 2020-09-01
NCT01208896 Allogeneic Hematopoietic Stem Cell Transplantation After Reduced-intensity Conditioning for Relapsed Follicular Lymphoma https://ClinicalTrials.gov/show/NCT01208896 Completed University Hospital, Bordeaux 2017-09-28
NCT00794638 A Phase I Clinical Trial to Assess the Safety of SyB L-0501 in Combination With Rituximab to Patients With Aggressive B-cell Non-Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT00794638 Completed SymBio Pharmaceuticals 2010-03-31
NCT00783367 Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas https://ClinicalTrials.gov/show/NCT00783367 Active, not recruiting Abramson Cancer Center of the University of Pennsylvania 2012-11-14
NCT00770224 S0801 Iodine I 131 Tositumomab, Rituximab, and Combination Chemotherapy in Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT00770224 Completed Southwest Oncology Group 2017-04-30
NCT00769288 FAU in Treating Patients With Advanced Solid Tumors or Lymphoma https://ClinicalTrials.gov/show/NCT00769288 Completed National Cancer Institute (NCI) 2013-12-31
NCT00742144 Ofatumumab in Japanese Patients With CD20 Positive Follicular Lymphoma or Chronic Lymphocytic Leukemia https://ClinicalTrials.gov/show/NCT00742144 Completed GlaxoSmithKline 2009-11-18
NCT00723099 Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer https://ClinicalTrials.gov/show/NCT00723099 Completed Fred Hutchinson Cancer Research Center 2018-07-31
NCT00720135 Fusion Protein Cytokine Therapy After Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT00720135 Completed City of Hope Medical Center 2014-07-31
NCT00719472 A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin’s Lymphoma (RATE) https://ClinicalTrials.gov/show/NCT00719472 Completed Genentech, Inc. 2011-05-31
NCT00715208 Phase 2 Study of VELCADE (Bortezomib) in Patients With Relapsed Follicular Lymphoma https://ClinicalTrials.gov/show/NCT00715208 Completed Millennium Pharmaceuticals, Inc. 2011-02-28
NCT00711828 Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Low-Grade Follicular Lymphoma, Waldenstrom Macroglobulinemia, or Mantle Cell Lymphoma https://ClinicalTrials.gov/show/NCT00711828 Completed Mayo Clinic 2013-11-30
NCT00696735 High-Dose Therapy Treatment in Patients With Follicular Lymphoma https://ClinicalTrials.gov/show/NCT00696735 Completed French Innovative Leukemia Organisation 2003-05-31
NCT00695786 Lenalidomide in Combination With Rituximab in Treating Participants With Stage III/IV Indolent Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT00695786 Active, not recruiting M.D. Anderson Cancer Center 2020-06-30
NCT00636792 A Phase II Study of VELCADE (Bortezomib) in Combination With Bendamustine and Rituximab in Subjects With Relapsed or Refractory Follicular Lymphoma https://ClinicalTrials.gov/show/NCT00636792 Completed Millennium Pharmaceuticals, Inc. 2010-05-31
NCT00634179 A Phase I/II Trial of VR-CHOP in Lymphoma Patients https://ClinicalTrials.gov/show/NCT00634179 Completed Emory University 2015-11-30
NCT00621452 Genetically Engineered Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Indolent B-Cell Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT00621452 Completed Fred Hutchinson Cancer Research Center 2014-01-31
NCT00608361 Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery https://ClinicalTrials.gov/show/NCT00608361 Completed National Cancer Institute (NCI) 2014-08-31
NCT00601718 Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma https://ClinicalTrials.gov/show/NCT00601718 Completed University of Washington 2010-06-30
NCT00574730 CHOP/Rituximab Followed by Maintenance PEG Intron in Treatment of Indolent/Follicular Non-Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT00574730 Completed University of Nebraska 2005-08-31
NCT00553501 Epratuzumab and Rituximab in Treating Patients With Previously Untreated Follicular Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT00553501 Completed Alliance for Clinical Trials in Oncology 2010-07-31
NCT00546793 Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL https://ClinicalTrials.gov/show/NCT00546793 Completed Immunomedics, Inc. 2013-03-31
NCT00536601 High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors https://ClinicalTrials.gov/show/NCT00536601 Completed Roswell Park Cancer Institute 2018-07-09
NCT00530140 Idiotypic Vaccination for Follicular Lymphoma Patients https://ClinicalTrials.gov/show/NCT00530140 Recruiting Clinica Universidad de Navarra, Universidad de Navarra 2013-09-30
NCT00509184 Rituximab and Involved Field Radiotherapy in Early Stage Follicular Lymphoma https://ClinicalTrials.gov/show/NCT00509184 Completed Heidelberg University 2013-04-30
NCT00499811 Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver Dysfunction https://ClinicalTrials.gov/show/NCT00499811 Completed National Cancer Institute (NCI) 2011-08-31
NCT00494780 Ofatumumab (Humax-CD20) With CHOP (Cyclophosphamide,Doxorubicin, Vincristine, Predisolone) in Follicular Lymphoma (FL) Patients https://ClinicalTrials.gov/show/NCT00494780 Completed GlaxoSmithKline 2009-04-30
NCT00489203 Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer https://ClinicalTrials.gov/show/NCT00489203 Completed Fred Hutchinson Cancer Research Center 2010-11-30
NCT00487305 Vaccination for the Treatment of Previously Untreated or Relapsed Follicular Lymphoma https://ClinicalTrials.gov/show/NCT00487305 Active, not recruiting Dana-Farber Cancer Institute 2020-08-31
NCT00475644 A Study of Enzastaurin in Participants With Follicular Lymphoma https://ClinicalTrials.gov/show/NCT00475644 Completed Eli Lilly and Company 2012-04-30
NCT00458731 Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma https://ClinicalTrials.gov/show/NCT00458731 Completed National Cancer Institute (NCI) 2013-12-31
NCT00440388 Safety & Efficacy Study of AT-101 in Combination w/ Rituximab in Previously Untreated Grade I-II Follicular Non-Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT00440388 Completed Ascenta Therapeutics 2008-11-30
NCT00438880 Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT00438880 Completed Mayo Clinic 2010-10-31
NCT00428142 Bortezomib, Combination Chemotherapy, and Rituximab as First-Line Therapy in Treating Patients With Stage III or Stage IV Follicular Non-Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT00428142 Completed Canadian Cancer Trials Group 2011-04-30
NCT00427856 Safety and Efficacy of Single Agent Obatoclax Mesylate (GX15-070MS) Followed by a Combination With Rituximab for Previously-untreated Follicular Lymphoma (FL) https://ClinicalTrials.gov/show/NCT00427856 Completed Teva Pharmaceutical Industries 2009-02-28
NCT00408681 Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant https://ClinicalTrials.gov/show/NCT00408681 Completed Fred Hutchinson Cancer Research Center 2010-11-30
NCT00406809 A Study of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies https://ClinicalTrials.gov/show/NCT00406809 Completed AbbVie 2016-10-31
NCT00394836 HuMax-CD20 i(Ofatumumab) n Follicular Lymphoma (FL) Patients Refractory to Rituximab https://ClinicalTrials.gov/show/NCT00394836 Completed GlaxoSmithKline 2009-04-30
NCT00393107 Safety and Efficacy of Fludarabine and Cyclophosphamide + Rituximab https://ClinicalTrials.gov/show/NCT00393107 Completed Gruppo Italiano Studio Linfomi NA
NCT00799461 Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications https://ClinicalTrials.gov/show/NCT00799461 Completed Fred Hutchinson Cancer Research Center 2011-11-30
NCT00366275 Immunochemotherapy, in Vivo Purging, PBSC Mobilization and Autotransplant in Relapsed or Refractory Follicular Lymphoma https://ClinicalTrials.gov/show/NCT00366275 Completed IRCCS Policlinico S. Matteo 2007-01-31
NCT00348985 PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas https://ClinicalTrials.gov/show/NCT00348985 Completed National Cancer Institute (NCI) 2010-01-31
NCT00343798 A Pilot Study to Evaluate the Co-Infusion of Ex Vivo Expanded Cord Blood Cells With an Unmanipulated Cord Blood Unit in Patients Undergoing Cord Blood Transplant for Hematologic Malignancies https://ClinicalTrials.gov/show/NCT00343798 Completed Fred Hutchinson Cancer Research Center 2013-07-31
NCT00317096 FCM Versus R-FCM Followed by R-Maintenance or Observation Only https://ClinicalTrials.gov/show/NCT00317096 Active, not recruiting Ludwig-Maximilians - University of Munich 2001-06-30
NCT00315731 A Study Of Pharmacokinetics, Whole Body And Organ Dosimetry, And Biodistribution Of Fission-Derived Iodine I 131 Tositumomab (BEXXAR®) For Patients With Previously Untreated Or Relapsed Follicular Or Transformed Non-Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT00315731 Completed GlaxoSmithKline 2006-12-04
NCT00293345 3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma https://ClinicalTrials.gov/show/NCT00293345 Completed National Cancer Institute (NCI) 2012-10-31
NCT00290511 Rituximab, Fludarabine, Mitoxantrone, Dexamethasone (R-FND) Plus Zevalin for High-Risk Follicular Lymphoma https://ClinicalTrials.gov/show/NCT00290511 Active, not recruiting M.D. Anderson Cancer Center 2020-08-24
NCT00290472 CCI-779 in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin’s Lymphoma or Chronic Lymphocytic Leukemia https://ClinicalTrials.gov/show/NCT00290472 Completed National Cancer Institute (NCI) 2010-04-30
NCT00275431 Phase II Safety and Efficacy Study of Single-agent AT-101 in Patients With Relapsed or Refractory B-cell Malignancies https://ClinicalTrials.gov/show/NCT00275431 Completed Ascenta Therapeutics 2008-12-31
NCT00275080 Vorinostat and Decitabine in Treating Patients With Advanced Solid Tumors or Relapsed or Refractory Non-Hodgkin’s Lymphoma, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Chronic Myelogenous Leukemia https://ClinicalTrials.gov/show/NCT00275080 Completed National Cancer Institute (NCI) 2009-11-30
NCT00268983 Comparison Of Rituximab Versus Tositumomab and Iodine I 131 Tositumomab (BEXXAR® Therapeutic Regimen) For Patients With Relapsed Follicular Non-Hodgkins Lymphoma https://ClinicalTrials.gov/show/NCT00268983 Completed GlaxoSmithKline 2009-09-30
NCT00253630 Vorinostat in Treating Patients With Low-Grade Non-Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT00253630 Completed National Cancer Institute (NCI) 2016-05-31
NCT00244855 Rituximab and Dexamethasone in Treating Patients With Low-Grade Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT00244855 Completed Fred Hutchinson Cancer Research Center 2008-12-31
NCT00238238 Rituximab and/or Lenalidomide in Treating Patients With Follicular Non-Hodgkin’s Lymphoma That is Not Refractory to Rituximab https://ClinicalTrials.gov/show/NCT00238238 Completed Alliance for Clinical Trials in Oncology 2012-06-30
NCT00201877 Velcade (Bortezomib, PS-341) and Rituximab in Relapsed/Refractory Mantle Cell and Follicular Non-Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT00201877 Completed Ohio State University Comprehensive Cancer Center 2009-06-30
NCT00193492 A Study of Rituximab and Bevacizumab in Patients With Follicular Non-Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT00193492 Completed SCRI Development Innovations, LLC 2013-03-31
NCT00193440 Rituximab and Chemotherapy Followed by Ibritumomab Tiuxetan as Treatment for Low Grade Follicular Non-Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT00193440 Completed SCRI Development Innovations, LLC 2004-04-30
NCT00185393 Treatment With [90]Y-Ibritumomab Tiuxetan Versus no Treatment in Patients With Follicular Non Hodgkin Lymphoma (Stage III or IV) Having Achieved a Partial or Complete Remission After First Line Chemotherapy https://ClinicalTrials.gov/show/NCT00185393 Completed Bayer NA
NCT00177554 Phase II Trial of CHOP-R Followed by Zevalin and Rituxan in Follicular Lymphoma https://ClinicalTrials.gov/show/NCT00177554 Completed University of Pittsburgh 2007-05-31
NCT00169208 Fludarabine, Mitoxantrone and Rituximab in Relapsed or Primary Failing Advanced Follicular Non-Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT00169208 Completed Lymphoma Study Association 2006-12-31
NCT00140582 Primary Rituximab and Maintenance https://ClinicalTrials.gov/show/NCT00140582 Completed Lymphoma Study Association 2007-05-31
NCT00140569 Randomized Study for Patients With Follicular Lymphoma Needing Treatment https://ClinicalTrials.gov/show/NCT00140569 Completed Lymphoma Study Association NA
NCT00136552 Study for Newly Diagnosed Follicular Lymphoma Patients With a Large Tumor Burden https://ClinicalTrials.gov/show/NCT00136552 Completed Lymphoma Study Association NA
NCT00119392 Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT00119392 Completed Fred Hutchinson Cancer Research Center 2009-07-31
NCT00118352 Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer https://ClinicalTrials.gov/show/NCT00118352 Completed Fred Hutchinson Cancer Research Center 2010-07-31
NCT00118170 Sorafenib in Treating Patients With Metastatic or Unresectable Solid Tumors, Multiple Myeloma, or Non-Hodgkin’s Lymphoma With or Without Impaired Liver or Kidney Function https://ClinicalTrials.gov/show/NCT00118170 Completed National Cancer Institute (NCI) 2007-05-31
NCT00115700 Radiotherapy Versus Radiotherapy Plus Chemotherapy in Early Stage Follicular Lymphoma https://ClinicalTrials.gov/show/NCT00115700 Active, not recruiting Trans-Tasman Radiation Oncology Group (TROG) 2021-12-31
NCT00112593 Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer https://ClinicalTrials.gov/show/NCT00112593 Completed Fred Hutchinson Cancer Research Center 2014-11-30
NCT00110071 Iodine I 131 Tositumomab and Fludarabine Phosphate in Treating Older Patients Who Are Undergoing an Autologous or Syngeneic Stem Cell Transplant for Relapsed or Refractory Non-Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT00110071 Completed Fred Hutchinson Cancer Research Center 2011-06-30
NCT00105001 Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer https://ClinicalTrials.gov/show/NCT00105001 Completed Fred Hutchinson Cancer Research Center 2011-05-31
NCT00098891 MS-275 and Isotretinoin in Treating Patients With Metastatic or Advanced Solid Tumors or Lymphomas https://ClinicalTrials.gov/show/NCT00098891 Completed National Cancer Institute (NCI) 2008-03-31
NCT00089271 17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphomas https://ClinicalTrials.gov/show/NCT00089271 Completed National Cancer Institute (NCI) 2010-06-30
NCT00089011 Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer https://ClinicalTrials.gov/show/NCT00089011 Completed Fred Hutchinson Cancer Research Center 2014-03-31
NCT00003196 Low-Dose Total Body Irradiation and Donor Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Patients With Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma https://ClinicalTrials.gov/show/NCT00003196 Completed Fred Hutchinson Cancer Research Center 2002-04-30
NCT00006251 Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer https://ClinicalTrials.gov/show/NCT00006251 Completed Fred Hutchinson Cancer Research Center 2005-09-30
NCT00082888 Tipifarnib in Treating Patients With Relapsed or Refractory Lymphoma https://ClinicalTrials.gov/show/NCT00082888 Completed National Cancer Institute (NCI) 2009-05-20
NCT00082784 Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell Neoplasms https://ClinicalTrials.gov/show/NCT00082784 Completed National Cancer Institute (NCI) 2012-10-31
NCT00081809 A Safety and Effectiveness Study of Vaccine Therapy in Patients With Indolent Lymphoma https://ClinicalTrials.gov/show/NCT00081809 Completed Agenus Inc. 2005-06-30
NCT00005799 Fludarabine Phosphate, Low-Dose Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer https://ClinicalTrials.gov/show/NCT00005799 Completed Fred Hutchinson Cancer Research Center 2002-07-31
NCT00078858 Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant https://ClinicalTrials.gov/show/NCT00078858 Completed Fred Hutchinson Cancer Research Center 2006-01-31
NCT00077155 Cilengitide (EMD 121974) in Treating Patients With Advanced Solid Tumors or Lymphoma https://ClinicalTrials.gov/show/NCT00077155 Completed National Cancer Institute (NCI) 2010-06-30
NCT00073918 Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT00073918 Completed Fred Hutchinson Cancer Research Center 2011-10-02
NCT00072514 Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies https://ClinicalTrials.gov/show/NCT00072514 Completed Fred Hutchinson Cancer Research Center 2008-07-31
NCT00068315 Bortezomib and Fludarabine With or Without Rituximab in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin’s Lymphoma or Chronic Lymphocytic Leukemia https://ClinicalTrials.gov/show/NCT00068315 Completed National Cancer Institute (NCI) 2008-12-31
NCT00003210 Interleukin-12 in Treating Patients With Previously Treated Non-Hodgkin’s Lymphoma or Hodgkin’s Disease https://ClinicalTrials.gov/show/NCT00003210 Completed National Cancer Institute (NCI) 2003-11-30
NCT00020462 Vaccine Therapy Plus Interleukin-2 in Treating Patients With Stage III, Stage IV, or Recurrent Follicular Lymphoma https://ClinicalTrials.gov/show/NCT00020462 Completed National Cancer Institute (NCI) NA
NCT00062894 Study of Untreated or Transformed Follicular Non-Hodgkin’s Lymphoma With Fission-Derived Iodine I 131 Tositumomab https://ClinicalTrials.gov/show/NCT00062894 Completed GlaxoSmithKline NA
NCT00795769 Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant https://ClinicalTrials.gov/show/NCT00795769 Completed Fred Hutchinson Cancer Research Center 2009-06-09
NCT00060684 Dose Ranging Trial for Pixantrone in the FND-R Variant Regimen in Indolent Non-Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT00060684 Completed CTI BioPharma 2005-01-31
NCT00058305 Bryostatin 1 Plus Vincristine in Treating Patients With Progressive or Relapsed Non-Hodgkin’s Lymphoma After Bone Marrow or Stem Cell Transplantation https://ClinicalTrials.gov/show/NCT00058305 Completed National Cancer Institute (NCI) 2007-12-31
NCT00058227 Alvocidib, Fludarabine Phosphate, and Rituximab in Treating Patients With Lymphoproliferative Disorders or Mantle Cell Lymphoma https://ClinicalTrials.gov/show/NCT00058227 Completed National Cancer Institute (NCI) 2009-02-28
NCT00054639 Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT00054639 Completed National Cancer Institute (NCI) 2010-01-31
NCT00054483 Bortezomib in Treating Patients With Advanced Cancer and Kidney Dysfunction https://ClinicalTrials.gov/show/NCT00054483 Completed National Cancer Institute (NCI) 2009-09-30
NCT00049504 Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer https://ClinicalTrials.gov/show/NCT00049504 Completed Fred Hutchinson Cancer Research Center 2011-03-31
NCT00040846 Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies https://ClinicalTrials.gov/show/NCT00040846 Completed Fred Hutchinson Cancer Research Center 2009-12-31
NCT00026182 Rituximab and Interleukin-12 in Treating Patients With B-Cell Non-Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT00026182 Completed National Cancer Institute (NCI) 2005-02-28
NCT00025415 Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction https://ClinicalTrials.gov/show/NCT00025415 Completed National Cancer Institute (NCI) 2005-01-31
NCT00022581 Thalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT00022581 Completed National Cancer Institute (NCI) 2004-12-31
NCT00017381 Monoclonal Antibody Therapy and Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT00017381 Completed National Cancer Institute (NCI) 2007-12-31
NCT00014235 Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies https://ClinicalTrials.gov/show/NCT00014235 Completed Fred Hutchinson Cancer Research Center 2005-02-28
NCT00010192 Rituximab Plus Interleukin-2 in Treating Patients With Hematologic Cancer https://ClinicalTrials.gov/show/NCT00010192 Completed National Cancer Institute (NCI) 2003-01-31
NCT00006473 Oxaliplatin in Treating Patients With Relapsed or Refractory Non-Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT00006473 Completed National Cancer Institute (NCI) 2006-02-28
NCT00004241 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma https://ClinicalTrials.gov/show/NCT00004241 Completed National Cancer Institute (NCI) 2006-05-31
NCT00003970 Genetic Testing Plus Irinotecan in Treating Patients With Solid Tumors or Lymphoma https://ClinicalTrials.gov/show/NCT00003970 Completed National Cancer Institute (NCI) 2003-10-31
NCT00003204 Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Stage III or Stage IV Low-Grade Non-Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT00003204 Completed National Cancer Institute (NCI) 2006-05-31
NCT00002649 Interleukin-2 or Observation Following Radiation Therapy, Combination Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT00002649 Completed National Cancer Institute (NCI) 2006-11-30
NCT00023764 Bortezomib in Treating Patients With Lymphoproliferative Disorders https://ClinicalTrials.gov/show/NCT00023764 Completed National Cancer Institute (NCI) 2009-03-31
NCT00001572 Vaccination of Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype https://ClinicalTrials.gov/show/NCT00001572 Completed National Institutes of Health Clinical Center (CC) 1999-07-31
NCT00001512 Active Specific Immunotherapy for Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype Antigen Vaccines https://ClinicalTrials.gov/show/NCT00001512 Completed National Institutes of Health Clinical Center (CC) 2010-03-05

Observational Studiess

#If less then 500 studies

nct_id brief_title link overall_status source primary_completion_date
NCT03374137 Observational Study to Monitor Safety and Effectiveness of Obinutuzumab in Follicular Lymphoma or Previously Untreated Chronic Lymphocytic Leukemia https://ClinicalTrials.gov/show/NCT03374137 Recruiting Hoffmann-La Roche 2020-09-30
NCT03087929 Follow-up Trial of Rituximab Interferon Transplant Trial: Study Drug-Rituximab and Alpha Interferon https://ClinicalTrials.gov/show/NCT03087929 Completed Sunnybrook Health Sciences Centre 2017-03-15
NCT02978898 CD180 Overexpression in Follicular Lymphoma https://ClinicalTrials.gov/show/NCT02978898 Completed Hospices Civils de Lyon 2014-06-30
NCT02951871 Causes of Death in Follicular Lymphoma: a Single Center Retrospective Analysis https://ClinicalTrials.gov/show/NCT02951871 Completed Hospices Civils de Lyon 2016-01-31
NCT02536664 Non-Interventional Study to Examine Rituximab Treatment in Follicular Lymphoma Participants https://ClinicalTrials.gov/show/NCT02536664 Completed Hoffmann-La Roche 2014-06-30
NCT02472756 A Study of Rituximab in Combination With Chemotherapy in Relapsed/Refractory Follicular Lymphoma https://ClinicalTrials.gov/show/NCT02472756 Completed Hoffmann-La Roche 2014-05-30
NCT02461290 Rituximab Therapy in Follicular Lymphoma in Combination With Chemotherapy - REFLECT 1 https://ClinicalTrials.gov/show/NCT02461290 Completed Hoffmann-La Roche 2013-11-30
NCT02316613 Prospective Observational Study on the Management of Patients With Relapsed or Refractory Follicular Lymphoma (OLYMPE) https://ClinicalTrials.gov/show/NCT02316613 Completed Hoffmann-La Roche 2013-04-30
NCT02240316 An Observational Study of Patients With Malignant Lymphomas Treated With MabThera® SC in Everyday Clinical Practice https://ClinicalTrials.gov/show/NCT02240316 Completed Hoffmann-La Roche 2019-07-22
NCT03190928 Clonal Evolution in Follicular Lymphoma https://ClinicalTrials.gov/show/NCT03190928 Recruiting National Institutes of Health Clinical Center (CC) 2022-07-01
NCT01684865 An Observational Study of First-Line Maintenance Rituximab (MabThera/Rituxan) in Participants With Follicular Non-Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT01684865 Completed Hoffmann-La Roche 2017-11-27
NCT01584141 Study of Lymphoma in Asia https://ClinicalTrials.gov/show/NCT01584141 Completed National Institutes of Health Clinical Center (CC) NA
NCT01406782 DNA Analysis in Influencing Response to Rituximab in Samples From Patients With Follicular Lymphoma Treated on ECOG-E4402 https://ClinicalTrials.gov/show/NCT01406782 Completed Eastern Cooperative Oncology Group 2012-01-13
NCT04048395 Clinical Outcomes of Early-progressed Follicular Lymphoma in Korea https://ClinicalTrials.gov/show/NCT04048395 Recruiting Samsung Medical Center 2020-04-30
NCT04034056 Untreated FolliculaR Lymphoma Treated With OBinituzumAb in a Non-interventional Study (URBAN) https://ClinicalTrials.gov/show/NCT04034056 Recruiting Hoffmann-La Roche 2024-12-30
NCT03663894 Clinical Characteristics and Outcomes of Relapsed Follicular Lymphoma After Autologous Stem Cell Transplantation at Rituximab Era https://ClinicalTrials.gov/show/NCT03663894 Completed Hospices Civils de Lyon 2017-12-15
NCT03568929 Safety Profile of Idelalisib in Patients With Refractory Follicular Lymphoma https://ClinicalTrials.gov/show/NCT03568929 Recruiting Gilead Sciences 2020-10-31
NCT03525665 Study on the Role of FDG-PET in Patients With FL at Time of Relapse/Progression https://ClinicalTrials.gov/show/NCT03525665 Completed Fondazione Italiana Linfomi ONLUS 2019-12-30
NCT03436602 Personalized Risk Stratification Model of Follicular Lymphoma Patients https://ClinicalTrials.gov/show/NCT03436602 Recruiting Oncology Institute of Southern Switzerland 2021-03-31
NCT01199562 Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant https://ClinicalTrials.gov/show/NCT01199562 Completed City of Hope Medical Center 2013-12-31
NCT01164696 A Prospective Observational Study to Evaluate the Quality of Life and the Costs in a Real Life Setting in Patients Who Are Treated With 90Y-Zevalin https://ClinicalTrials.gov/show/NCT01164696 Completed Bayer 2009-05-31
NCT01150643 Biomarkers in Samples From Patients With Follicular Lymphoma Treated With Rituximab https://ClinicalTrials.gov/show/NCT01150643 Completed Eastern Cooperative Oncology Group 2011-01-06
NCT01131221 S8947-9800-9911-0016A Vitamin D Insufficiency in Determining Prognosis in Patients With Newly Diagnosed Follicular Lymphoma https://ClinicalTrials.gov/show/NCT01131221 Completed Southwest Oncology Group 2011-09-30
NCT01057459 DNA Analysis in Predicting Response to Antibody Therapy in Patients With Follicular Lymphoma Treated on Clinical Trials CALGB-50402 or CALGB-50701 https://ClinicalTrials.gov/show/NCT01057459 Completed Alliance for Clinical Trials in Oncology 2014-06-23
NCT01000753 Collecting and Storing Tissue Samples From Patients With Rare or Cutaneous Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT01000753 Active, not recruiting Children’s Oncology Group 2007-06-01
NCT00933127 S8809-S9800-S9911-S9704-A Study of Blood and Tissue Samples From Patients With Follicular Lymphoma Treated With Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone https://ClinicalTrials.gov/show/NCT00933127 Completed Southwest Oncology Group 2012-06-30
NCT00915096 Positron Emission Tomography (PET)-Scan in the Evaluation of High Tumor Burden Follicular Lymphoma https://ClinicalTrials.gov/show/NCT00915096 Completed Lymphoma Study Association 2011-05-10
NCT00898963 Biomarkers in Patients With Stage III or Stage IV Follicular Lymphoma Treated on Clinical Trial E-1496 https://ClinicalTrials.gov/show/NCT00898963 Completed Eastern Cooperative Oncology Group 2011-12-21
NCT00896922 S8809-S9800-S9911TM- Biological Markers in Patients With Follicular Lymphoma Treated on Clinical Trial SWOG-8809, SWOG-9800, or SWOG-9911 https://ClinicalTrials.gov/show/NCT00896922 Completed Southwest Oncology Group 2009-10-31
NCT02378337 Defining PET / CT Protocols With Optimized F18-FDG (Fluorodeoxyglucose) Dose, Focusing on Reduced Radiation Dose and Improved Image Quality https://ClinicalTrials.gov/show/NCT02378337 Completed Hospital Sao Rafael 2015-08-31
NCT00097565 An Observational Study of Treatment, Outcomes, and Prognosis in Patients With Follicular Non-Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT00097565 Completed Genentech, Inc. 2014-03-31

Registries

#If less then 500 registries

nct_id brief_title link overall_status source primary_completion_date
NCT04342117 Observational Trial of Real-World Treatment Utilization and Effectiveness of PI3K-inhibitors in CLL/SLL and FL https://ClinicalTrials.gov/show/NCT04342117 Recruiting Verastem, Inc. 2023-04-30